| Ytd | -21.00% | |
| 1y | -72.56% |
| Open | 12.80 | Prev Close | 12.59 | Low | 11.97 | High | 12.80 | Mkt Cap | 196.71M |
| Vol | 0.00 | Avg Vol | 534.21K | EPS | -12.94 | P/E | -0.95 | Forward P/E | -0.01 |
| Beta | 2.08 | Short Ratio | 0.35 | Inst. Own | 0.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 11.63 | 200-d Avg | 14.58 | 1yr Est | 5.83 |
TNXP News
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Tonix Pharmaceuticals NASDAQ: TNXP reported second-quarter 2026 net product revenue of approximately
TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Comm
BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasda
Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in
BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasda
Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003
Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or "the Company"), a full
New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of appr
HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluat
Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades &a
Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP s
BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasda
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are trading higher Monday after the company
Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides
Real-world analysis of three years of closed claims data from Symphony Health, focused on the third
Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-
Real-world analysis of three years of closed claims data from Symphony Health focused on the third y
BERKELEY HEIGHTS, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq
BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq
In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patient
Agreement with leading group purchasing organization (GPO) provides access to approximately 35 milli
https://www.who.int/news/item/09-06-2025-fourth-meeting-of-the-international-health-regulations-(200
Gainers
During Thursday's session, 406 companies made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
During Wednesday's trading, 103 companies set new 52-week lows.
On Thursday, 221 companies hit new 52-week lows.
On Wednesday, 129 stocks made new 52-week lows.
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% o